Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VaxcoTeii (also known as COVID-away Nasal Spray) is a peptide-based intranasal spray developed by Youfeng Biotechnology (YoufengBio). It utilizes the proprietary Ii-Key peptide technology, which is designed to enhance the presentation of antigens to the immune system by modulating MHC class II molecules. Specifically, the Ii-Key peptide (a segment of the invariant chain) facilitates the charging of antigenic peptides into the MHC class II binding groove, thereby boosting CD4+ T-cell mediated immune responses. The product is intended for the prevention and treatment of COVID-19 (SARS-CoV-2) and has reported antibacterial activity against *Escherichia coli* and *Staphylococcus aureus*. It is administered intranasally and is positioned as both an antiviral and an antibacterial agent.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on VaxcoTeii.